RecruitingNCT00899626
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Novel Colon Cancer Markers in Gastrointestinal Tissue and Biofluids
Sponsor
Vanderbilt University Medical Center
Enrollment
5,000 participants
Start Date
Jun 1, 2002
Study Type
OBSERVATIONAL
Conditions
Summary
RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from patients with cancer and from healthy volunteers undergoing colonoscopy or endoscopy may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is looking at gastrointestinal biomarkers in tissue and biological fluid samples from patients and participants undergoing colonoscopy, endoscopy, or surgery.
Eligibility
Min Age: 18 Years
Inclusion Criteria11
- DISEASE CHARACTERISTICS:
- Undergoing colonoscopy or endoscopy for diagnostic or screening purposes at the Vanderbilt University Medical Center or at the Veterans Affairs Medical Center AND
- Meets 1 of the following criteria:
- Diagnosis of gastrointestinal (GI) cancer, polyps, or inflammatory bowel disease
- History of previously treated GI cancer, polyps, or inflammatory bowel disease
- PATIENT CHARACTERISTICS:
- Capable of giving informed consent
- Not mentally or medically impaired
- No bleeding disorder
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00899626
Related Trials
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT056635158 locations
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT072774391 location
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location